Global sales of Copaxone® (20 mg/mL and 40 mg/mL), the leading multiple sclerosis therapy in the U.S. and globally, amounted to $1.1 billion, an increase of 12% compared to the second quarter of 2014.
In the United States, sales of Copaxone® amounted to $870 million, an increase of 31% compared to the second quarter of 2014. The increase was mainly due to higher sales volume in the second quarter of 2015 as well as price increases in August 2014 and January 2015. In addition, our U.S. Copaxone® revenues in the second quarter of 2014 were relatively low following the launch of Copaxone® 40 mg/mL in January 2014. At the end of the second quarter of 2015, according to June 2015 IMS data, our U.S. market shares for the Copaxone® products in terms of new and total prescriptions were 23.8% and 31.2%, respectively. Copaxone® 40 mg/mL accounted for 68.5% of total Copaxone® prescriptions in the U.S.
In June 2015, Sandoz launched its once daily generic version of Copaxone® 20 mg/mL, Glatopa®, in the United States. They sure like to raise prices. Think we will be fine
With competition heating up in their main earnings driver Copaxone, see this as an answer to increased earnings pressure of the next few years. Either this purchase or the Mylan deal will give them the breathing room they need. Watch what they say on earnings conference call.